Tarson Products shares rally after tepid debut

Tarson Products shares rally after tepid debut

Tarsons Products shares rallied sharply on Friday, minutes after having made a tepid debut on the stock exchanges. The stock price rose 20% from the IPO price within minutes to trade at Rs 795 per share, after having listed at a lukewarm Rs 700 apiece.
The stock began trading at Rs 700 per share, up Rs 38 or 5.74% from the upper end of the IPO price band of Rs 662 apiece.
Tarsons Products, a life sciences company, garnered a strong response from investors earlier this month, with all pockets of investors oversubscribing their portion by a strong margin. Overall the IPO of Tarsons Products was subscribed a massive 77.49 times. On listing the stock had a market capitalization of Rs 3,724 crore.
The IPO of Tarsons Products was subscribed 115 times by Qualified Institutional Buyers (QIB), while Non-Institutional Investors’ subscription was more than 184 times the reserved quota.

Retail subscription for Tarsons Products was more than 10 times their portion. Post issue the shareholding of promoters of the company has dropped to 47.3% from 50.78% earlier while public shareholding is up at 52.7% from 49.22%.
Tarsons Products is engaged in the designing, development, manufacturing and marketing of consumables and reusables used in various laboratories.
The company has a diversified product portfolio with over 1,700 SKUs across 300 products catering to research organizations, academic institutions, pharmaceutical companies, contract research organizations, diagnostic companies, and hospitals.
In terms of valuations, considering the TTM (June 2021) adjusted EPS of Rs.16.30 on post-issue basis, the company is going to list at a P/E of 40.61.

Disclaimer –
This document is meant for the recipient only for use as intended and not for circulation. This document should not be reproduced or copied or made available to others. The information contained herein is from the public domain or sources believed to be reliable. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be relied upon as such. Also above note is not a recommendation to Buy or SELL and is only a view based on facts and figures and we will be in no way responsible for any losses incurred by anyone who uses this information to either trade or invests securities mentioned herein.